We report incidence of NPM1-wildtype relapses in pts treated with VEN-based frontline tx in AML.   🔴Overall, absolute # of relapses in NPM1 AML after VEN is ⬇️  🔴the fraction of NPM1-wildtype relapses ⬆️ with the⬆️ intensity of chemo backbone added to VEN.  🔴 NPM1 wildtype

👉👉👉Important new paper led by Dr @sankalparoraMD & Prof @Daver_Leukemia just out in @JournalCancer #FLT3TKD #NPM1 for patient with AML #leusm #endcancer @sanamloghavi @GhayasIssa @NicholasShortMD @TapKadia @garciamanero @DrHKantarjian https://t.co/U0hjhHVQ5x

For the love of God😡There has to be a better way to utilize all this fancy #AI & make @ASH_hematology abstract submissions more efficient (for $85 a pop). Takes ~ hour ⏳to just add authors!!! 🤦🏻‍♀️ & here I am fearing AI may make my job obsolete… 😬not in this lifetime 😴

👉👉👉Leukemia Team together right after my annual #BPDCN Update Leukemia Wed noon grand rounds talk hosted by Dr @garciamanero ! @doctorpemm #endcancer | @DanielleHammo20 @DrHKantarjian @NitinJainMD @sanamloghavi @KMirza @mkonople @Transplant_Doc @FadiHaddad_MD @jayastuMD 🙌

👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials. #CLL

👉👉We report case series of 6 patients with T-ALL/LBL who developed rhabdomyolysis after receiving nelarabine 👉 Check CK if pt develops myalgia, unexplained rise in creatinine while on nelarabine @Dr_MSU @DrHKantarjian https://t.co/rEVtiPtWcX

#Myeloma Paper of the Day: Phase 2 study of dara/thal/dex in relapsed and/or refractory MM finds median PFS 16 months (9.4 if thal/len/pom refractory), ORR 82% (64% VGPR or better, 25% CR or better, 13% sCR), median DOR 19 mos, median OS 32.5 mos: https://t.co/dJMT1OYsxb. #mmsm

Myeloma Paper of the Day, June 18th, suggested by Robert Orlowski (@Myeloma_Doc) @MDAndersonNews @chngwj @jenweiying https://t.co/6nebMGuFC2 #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #RRMM #Myeloma #Daratumumab #Thalidomide

👉Leukemia team together @MDAndersonNews today! @doctorpemm @jenweiying @TapKadia @drvanthanab @r_sazevedo 🙌

#EHA25 #EHA2025 || So awesome to see our leading young superstar MDs Dr @jenweiying with Dr Alex Bazinet at the posters and senior author @TapKadia || 🙌 #endcancer #leusm

👉👉👉Just out in @AjHematology - our group’s new paper led by .@TapKadia & @DrHKantarjian || Ph2 study Results CPX-351+VEN for patients w/ R/R AML (n=33;44%2nd Salvage Tx or later;30%prior SCT:: ORR=46% w/CRc 39%) #leusm #endcancer | https://t.co/9Ej2XvReNZ | @sanamloghavi

👉👉👉Wonderful to get to spend some time with our friend & colleague @CRausch who is back in town this weekend ! @Marxk @TapKadia | #leusm

👉👉👉Amazing talk at the intersection of hemepath & leukemia and chance for a quick group photo afterward - by our own world-renowned faculty speaker Dr .@sanamloghavi in @MDAndersonNews Hematology Grand Rounds this AM !!! #leusm #hemepath #endcancer | @HemeReports

📝 A new study published in @BloodAdvances found that MRD clearance timing can serve as an important prognostic factor for patients with newly diagnosed #AML undergoing intensive chemotherapy. More news: https://t.co/UucMeHw5EC @jenweiying #AMLsm #MedNews #MedEd #leusm

👉👉👉The most Wonderful team to work with on a daily basis ➡️ our phenomenal @MDAndersonNews Leukemia Team !!!! | #leusm #MPNSM #BPDCN #PharmD #endcancer 🙏

👉Appreciation lunch for #CLL research team @MDAndersonNews Thank you for your ongoing commitment to patient care and research and innovation. 🙏🏽🙏🏽👏👏 #EndCancer #EndCLL @wwierda @DrHKantarjian

Updated results of our frontline trial of FLAG-IDA+VEN, showing CRc in 95% of newly diagnosed #AML. Responses were seen across all ELN22 risk groups, w/ 90% MRD neg. In RR AML, 79% first salvage & TP53wt attained CRc. @MDAndersonNews https://t.co/I7S7afDUbf @LeukemiaJnl

Early attainment of undetectable MRD by MFC is independently associated w/ improved RFS in newly diagnosed #AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT. @MDAndersonNews #Leukemia @ASH_hematology https://t.co/FfQ2J1JTHS

Duckworth: How many nations are in ASEAN? Hegseth: We have allies in South Korea, Japan, and Australia Duckworth: None of those countries are in ASEAN

I had the incredible opportunity to present our project highlighting relapse patterns after treatment with venetoclax in pts with AML at #ASH24 - thank you to @jenweiying and @TapKadia for your guidance and support 🙏🏼 @BCM_InternalMed @MDAndersonNews